Skip to main content

Table 1 General characteristics of the animal model (mean ± SEM)

From: Erythropoietin attenuates cardiac dysfunction by increasing myocardial angiogenesis and inhibiting interstitial fibrosis in diabetic rats

Parameters

Controls (n = 8)

DM rats (n = 8)

DM + EPO rats (n = 8)

LVD d (mm)

6.62 ± 0.36

7.48 ± 0.72*

6.78 ± 0.53▴

LVD s (mm)

3.57 ± 0.58

4.65 ± 0.74*

3.67 ± 0.65▴

EF (%)

79.4 ± 8.12

65.7 ± 5.49#

75.6 ± 4.87▴

Body weight (g) baseline

236 ± 7.9

241 ± 6.7

239 ± 8.8

Body weight (g) end-point

358 ± 13.8

293 ± 13.5#

332 ± 15.4▴

Heart rate (BPM)

411.8 ± 46.8

416.6 ± 67.2

376.9 ± 43.0

HW/BW (mg/g)

3.1 ± 0.14

4.5 ± 0.20#

3.3 ± 0.18▴

Blood glucose (mmol/L) baseline

4.55 ± 0.60

20.47 ± 1.46#

20.63 ± 1.62#

Blood glucose (mmol/L) end-point

4.13 ± 0.43

20.27 ± 1.20#

21.37 ± 1.53#

Erythrocyte numbers (1012/L) baseline

8.00 ± 0.43

7.84 ± 0.40

8.06 ± 0.23

Erythrocyte numbers (1012/L) end-point

8.16 ± 0.37

7.68 ± 0.34

8.23 ± 0.47

  1. *P < 0.05 vs control, #P <0.01 vs control, ▴P <0.05 vs diabetes.